Watch and Wait in Slow-Growing Lymphoma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how people with slow-growing lymphomas (like CLL, MZL, FL, or WM) feel during watchful waiting — when they are not on active treatment. It aims to see if patients are more anxious or worried, and how to best support them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with a slow-growing type of lymphoma (such as CLL/SLL, MZL, FL, or WM/LPL).
- You are currently being managed with a watch-and-wait approach (no active treatment like chemo or targeted therapy).
- You are able to read and fill out questionnaires on your own, and you agree to take part in the study.
- You are not currently receiving any active treatment for your lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This trial compares two approaches: continuing regular infusions of a drug called rituximab (a type of immunotherapy) versus simply watching and waiting, for people with a slow-growing lymphoma who cannot have chemo. Rituximab may help keep the lymphoma under control for a longer time, but it's not yet known which approach is better.
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
This study looks at quality of life in people age 70 and older with slow-growing (low-grade) B-cell non-Hodgkin lymphoma who haven’t been treated yet. It requires a geriatric (aging-focused) check before starting care, to see what helps older patients feel better during treatment.
This trial tests an oral medication called lisaftoclax for people with slow-growing B-cell lymphomas, such as CLL, Waldenström's macroglobulinemia, or marginal zone lymphoma. It may be an option if you haven't had treatment yet but can't take standard BTK inhibitor pills, or if you tried one BTK inhibitor and had to stop because of side effects.
Hear when a new Waldenström Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.